JP2012508575A - Ｆｏｘｐ３＋ナチュラルキラーＴ細胞および免疫関連疾患の治療方法 - Google Patents

Ｆｏｘｐ３＋ナチュラルキラーＴ細胞および免疫関連疾患の治療方法 Download PDF

Info

Publication number
JP2012508575A
JP2012508575A JP2011536276A JP2011536276A JP2012508575A JP 2012508575 A JP2012508575 A JP 2012508575A JP 2011536276 A JP2011536276 A JP 2011536276A JP 2011536276 A JP2011536276 A JP 2011536276A JP 2012508575 A JP2012508575 A JP 2012508575A
Authority
JP
Japan
Prior art keywords
cells
foxp3
natural killer
cell population
nkt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011536276A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012508575A5 (enExample
Inventor
リカルド シモエス ダ シルヴァ グラサ，ルイス
ソフィア フェレイラ モンテイロ，マルタ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto de Medicina Molecular Joao Lobo Antunes
Original Assignee
Instituto de Medicina Molecular Joao Lobo Antunes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto de Medicina Molecular Joao Lobo Antunes filed Critical Instituto de Medicina Molecular Joao Lobo Antunes
Publication of JP2012508575A publication Critical patent/JP2012508575A/ja
Publication of JP2012508575A5 publication Critical patent/JP2012508575A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
JP2011536276A 2008-11-13 2009-11-13 Ｆｏｘｐ３＋ナチュラルキラーＴ細胞および免疫関連疾患の治療方法 Pending JP2012508575A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11436208P 2008-11-13 2008-11-13
US61/114,362 2008-11-13
PT10476409 2009-09-25
PT104764 2009-09-25
PCT/PT2009/000060 WO2010056144A2 (en) 2008-11-13 2009-11-13 Foxp3+ natural kiler t-cells and the treatment of immune related diseases

Publications (2)

Publication Number Publication Date
JP2012508575A true JP2012508575A (ja) 2012-04-12
JP2012508575A5 JP2012508575A5 (enExample) 2013-01-17

Family

ID=42138978

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011536276A Pending JP2012508575A (ja) 2008-11-13 2009-11-13 Ｆｏｘｐ３＋ナチュラルキラーＴ細胞および免疫関連疾患の治療方法

Country Status (8)

Country Link
US (1) US20120114675A1 (enExample)
EP (1) EP2356222A2 (enExample)
JP (1) JP2012508575A (enExample)
CN (1) CN102216448A (enExample)
AU (1) AU2009314704A1 (enExample)
BR (1) BRPI0915255A2 (enExample)
CA (1) CA2743502A1 (enExample)
WO (1) WO2010056144A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102603892B (zh) * 2012-02-22 2013-10-30 尉军 一种肿瘤标志物foxp3抗原多肽及应用
ES3040431T3 (en) * 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
EP3838288A1 (en) * 2014-06-11 2021-06-23 polybiocept GmbH Expansion of lymphocytes with a cytokine composition for active cellular immunotherapy
TWI702290B (zh) * 2015-04-07 2020-08-21 富禾生醫股份有限公司 經修飾之自然殺手ｔ細胞、醫藥組合物及其用途
CN105039255A (zh) * 2015-09-09 2015-11-11 广州赛莱拉干细胞科技股份有限公司 一种nkt细胞诱导培养的添加剂及诱导培养的方法
CN107475194B (zh) * 2017-10-09 2018-07-24 天津长和生物技术有限公司 Nkt细胞培养基、培养方法及二者的应用
WO2020215034A1 (en) * 2019-04-19 2020-10-22 The Regents Of The University Of California An ampk/caspase-6 axis controls liver damage in nonalcoholic steatohepatitis
CN115768879A (zh) 2020-04-28 2023-03-07 莱尔免疫制药公司 用于培养细胞的方法
WO2025221808A1 (en) * 2024-04-15 2025-10-23 Trustees Of Tufts College Efficient epigenetic reprogramming of t effector cells into stable regulatory t cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530101A (ja) * 2000-04-11 2003-10-14 ユニバーシティ・オブ・サザン・カリフォルニア 抑制性Ｔ細胞を誘導するためにＴＧＦ−βを用いる移植拒絶反応を防止する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US20060057145A1 (en) * 2002-10-25 2006-03-16 Government Of The United States Of America As Represented By The Secretary, Dept. Of Health Methods to prevent tumor recurrence by blockade of tgf-beta

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530101A (ja) * 2000-04-11 2003-10-14 ユニバーシティ・オブ・サザン・カリフォルニア 抑制性Ｔ細胞を誘導するためにＴＧＦ−βを用いる移植拒絶反応を防止する方法

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CELL, vol. 133, no. 5, JPN6013029715, May 2008 (2008-05-01), pages 775 - 787, ISSN: 0002560530 *
CLINICAL MEDICINE & RESEARCH, vol. 1, JPN6013029713, 2003, pages 13 - 20, ISSN: 0002560529 *
DIABETES, vol. 57, no. 1, JPN6013029727, June 2008 (2008-06-01), pages 353 - 1239, ISSN: 0002560532 *
INT. IMMUNOL., vol. 23, no. 8, JPN6013029725, 2011, pages 473 - 484, ISSN: 0002560534 *
J. IMMUNOL., vol. 185, JPN6013029722, 2010, pages 2157 - 2163, ISSN: 0002560533 *
JOURNAL OF IMMUNOLOGY, vol. 169, no. 1, JPN6013029706, 2002, pages 31 - 38, ISSN: 0002560527 *
JOURNAL OF LEUKOCYTE BIOLOGY, vol. 81, JPN6013029718, 2006, pages 654 - 662, ISSN: 0002560531 *
PNAS, vol. 98, no. 5, JPN6013029709, 2001, pages 2577 - 2581, ISSN: 0002560528 *

Also Published As

Publication number Publication date
AU2009314704A1 (en) 2010-05-20
EP2356222A2 (en) 2011-08-17
BRPI0915255A2 (pt) 2018-02-06
CN102216448A (zh) 2011-10-12
US20120114675A1 (en) 2012-05-10
CA2743502A1 (en) 2010-05-20
WO2010056144A3 (en) 2010-07-22
WO2010056144A2 (en) 2010-05-20

Similar Documents

Publication Publication Date Title
Selck et al. Antigen-specific regulatory T cell therapy in autoimmune diseases and transplantation
JP7001575B2 (ja) Ｂ細胞の増加及び評価方法並びに疾患治療のための増加ｂ細胞の使用方法
Asnagli et al. Type 1 regulatory T cells specific for collagen type II as an efficient cell-based therapy in arthritis
Price et al. The role of dendritic cell subsets and innate immunity in the pathogenesis of type 1 diabetes and other autoimmune diseases
JP2012508575A (ja) Ｆｏｘｐ３＋ナチュラルキラーＴ細胞および免疫関連疾患の治療方法
Radhakrishnan et al. Reprogrammed FoxP3+ T regulatory cells become IL-17+ antigen-specific autoimmune effectors in vitro and in vivo
EP1812563B1 (en) Methods of generating antigen-specific cd4+cd25+ regulatory t cells, compositions and methods of use
Lerret et al. Donor-specific CD8+ Foxp3+ T cells protect skin allografts and facilitate induction of conventional CD4+ Foxp3+ regulatory T cells
US10260042B2 (en) Compositions and methods for diminishing an immune response
RU2563360C2 (ru) Композиции для лечения артрита
KR102768442B1 (ko) CD8+CD45RClow TREGS의 신규한 아집단 및 이들의 용도
Mathä et al. Migration of lung resident group 2 innate lymphoid cells link allergic lung inflammation and liver immunity
JP2000509604A (ja) サプレッサー細胞集団を生成するためのインターロイキン―１０の使用
JP2016539635A (ja) 抗原特異的調節性ｔ細胞の誘導方法
EP2595637B1 (en) Regulatory immune cells with enhanced targeted cell death effect
AU2017224499B2 (en) Pharmaceutical composition for preventing or treating regulatory T cell-mediated diseases
KR102100307B1 (ko) 인간 림프 기관-유래 억제성 기질 세포의 분리 및 용도
Buchele et al. Th17 cell-mediated colitis is positively regulated by interferon regulatory factor 4 in a T cell-extrinsic manner
WO2010129770A1 (en) Methods for expanding human t regulatory cells and uses of same
Selck et al. Regulatory T Cells for the Treatment of Autoimmune Diseases
Baum The Role of Interleukin-21 in the Chronic Rejection of Transplant Allografts and the Development of Type 1 Diabetes
Haddad Divergent Effects of OX40L on Regulatory T Cell Phenotype and Function: Implications for Type 1 Diabetes Therapy
Schenk et al. Purinergic control of T cell activation by ATP released through pannexin-1 hemichannels
Gray BSI 2010 Invited Speakers’ Abstracts

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121113

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130619

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131218